IFF to Expand Tastepoint Blueprint, Serving Mid-size Customers Around the World
3.12.2019 00:15:00 EET | Business Wire | Press release
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, announced its intention to expand its Tastepoint by IFF model in multiple geographies around the world and provide localized service to the dynamic middle-market customers in a variety of locations. Leveraging Frutarom’s large and well-established client base, the Company will enhance its offering to those customers while maintaining focus on the specific needs of their local market.
“When we established Tastepoint by IFF in 2017, its aim was to serve North America’s mid-market companies in the quick and agile way their business model requires, but offering them the advantage of IFF technologies,” said Matthias Haeni, Taste CEO, IFF. “As we integrate Frutarom into the IFF family around the world, we have a great opportunity to replicate our Tastepoint go-to-market blueprint in key markets as we underscore our commitment to serving the dynamic mid-market customer. It is an exciting time at IFF, and this is another great example of the benefits our combination brings to customers.”
Tastepoint’s brand promise is based on “the perfect blend of heart and science” with a focus on servicing customers with the “can-do” approach of a smaller company but backed by expertise traditionally reserved for companies with more global reach. Like the original Tastepoint by IFF established in North America, the new Tastepoints will offer customers an increased product portfolio through IFF’s Taste Design. In addition to traditional flavors and total solutions, the offerings will leverage an expanded naturals portfolio that includes colors, food protection and health ingredients. The Company will provide more specifics as the individual sites open.
IFF Chairman & CEO Andreas Fibig said, “Since the creation of Tastepoint, we have seen the value of the ’small enough to care, big enough to make it happen’ approach and the impact that it has on its customers. By continuing to focus on the mid-market companies with in-depth knowledge of their local needs and challenges, we will help deliver on IFF’s Vision 2021 strategy that keeps the customer at the center of all we do.”
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.
Say hello to Tastepoint by IFF
Tastepoint by IFF is the newest name in taste. We exist to be the spark that advances our customers, working side-by-side to create products that ignite the palate, and the imagination. As a product development partner with a fresh take on taste, we unite skill and soul, chemistry and creativity, freshness and familiarity. With more than a century of know-how and the resources of global powerhouse IFF at the ready, our innovation artists bring you the perfect blend of heart and science. We’re small enough to care, and big enough to make it happen – with speed and agility, together, we can tackle any challenge no matter the size. Learn more at www.tastepoint.com, Twitter, Instagram and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005800/en/
Contact information
IFF
Michael DeVeau
Head of Investor Relations and Communications & Divisional CFO, Scent
212.708.7164
Michael.DeVeau@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 09:00:00 EEST | Press release
Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidates that demonstrated real, measurable activity against tumors. This collaboration marks an important milestone for Okomera, which is signing its first commercial agreement with an international pharmaceutical group. Under the terms of the agreement, Servier will operate Okomera’s platform fully independently. Its teams will be able to ge
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8%, from accelerated bolt-on acquisitions (+2.7% contribution), net of
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 08:00:00 EEST | Press release
Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much faster than they can change how an organization works,” said Francesco Buquicchio, Global CEO of Egon Zehnder. “That gap matters. L
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company will present eight scientific abstracts, alongside a symposium and six Meet-the-Expert sessions, all highlighting the expanding benefits of Relfydess, Sculptra, and the Restylane range.1-8 Together, the data demonstrate Galderma’s commitment to meeting the evolving needs of patients and healthcare professionals through innovation that addresses growing needs, from menopause-related skin changes and regenerative aesthetic solutions, to body indications. Data across face and body indications showcase the power of Sculptra and Restylane Data on Sculptra, the first proven regenerative biostimulator, will be shared at AMWC Dubai, following its approval in the UAE expanding its current clinical application for the face to include key body areas:
Sihoo esittelee uuden sukupolven ergonomisia toimistoratkaisuja ORGATEC 2026 -messuilla20.10.2026 21:14:00 EEST | Tiedote
ORGATEC 2026 -messujen lähestyessä ergonomisten istuinratkaisujen asiantuntija Sihoo esittelee uuden sukupolven työympäristöratkaisujaan hallissa 8.1, osastoilla A-060 ja B-061. Messujen teeman ”Tiloista vuorovaikutukseen: tilojen suunnittelu jatkuvasti muuttuvassa maailmassa” mukaisesti Sihoo esittelee, kuinka mukautuva ergonominen suunnittelu tukee asentojen vaihtelua ja nykyaikaisten työympäristöjen muuttuvia tarpeita. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261020772047/fi/ Sihoo ORGATEC 2026 -messuilla Kölnissä Käyttötilanteisiin perustuva elämyksellinen tila Avoimeen tilakonseptiin perustuvalla Sihoon osastolla yhdistyvät oranssin ja valkoisen värimaailma, kerrokselliset kattorakenteet, läpikuultavat väliseinät ja integroitu valaistus. Korkeussäädettävillä työpöydillä ja näytöillä varustetut työpisteet sekä yhteistyöhön suunnitellut istuma-alueet jäljittelevät tuttuja toimistoympäristöjä ja havainnollistavat,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
